Tyr3-octreotaat (acetaat)

Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) [1].

12352209

Radionuclide-Drug Conjugates (RDCs)

Antibody-drug Conjugate/ADC Related

Cancer-programmed cell death

Cancer

99.76

O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45.CC(O)=O.CC(O)=O

C53H72N10O16S2

1169.33

[1]Capello A, et al., Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm. 2003 Oct;18 (5) :761-8.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10239A/Tyr3-Octreotate-acetate-SDS-MedChemExpress.pdf

Peptides

No Development Reported